Biotechnology firm Creative Biolabs has advanced non-IgG antibody production technologies, developing specialized techniques for producing IgE, IgM, and IgA antibodies with potential groundbreaking applications in medical research and therapeutic development.
The company has optimized expression systems using cell lines like CHO and HEK293, enabling high-efficiency antibody production. For IgE antibodies, the firm has refined purification strategies including affinity and ion exchange chromatography, addressing complex challenges in maintaining antibody stability and purity.
IgM antibody production represents another critical focus, with the company developing methods to manipulate pentameric and hexameric structures to enhance biological activity. Advanced purification techniques like three-step CHT/AIX/CIX and two-step PEG/AIX processes ensure high recovery rates meeting preclinical study standards.
Notably, the company's work on IgA antibodies highlights emerging potential in mucosal immunity research. By developing monomeric and dimeric IgA using multiple cell expression systems, Creative Biolabs is positioned to support fundamental studies and medicinal product development.
The advancement of non-IgG antibody technologies could significantly impact immunotherapy research, offering more sophisticated tools for investigating treatments in cancer, infectious diseases, and inflammatory conditions. By providing scalable, high-quality antibody solutions, the company is helping researchers explore innovative therapeutic approaches.
